Literature DB >> 29197072

Induction of mast cell accumulation by chymase via an enzymatic activity- and intercellular adhesion molecule-1-dependent mechanism.

Huiyun Zhang1,2, Junling Wang1, Ling Wang2, Mengmeng Zhan1, Shigang Li3, Zeman Fang4, Ciyan Xu4, Yanshan Zheng4, Shaoheng He1,2.   

Abstract

BACKGROUND AND
PURPOSE: Chymase is a unique, abundant secretory product of mast cells and a potent chemoattractant for eosinophils, monocytes and neutrophils, but little is known of its influence on mast cell accumulation. EXPERIMENTAL APPROACH: A mouse peritoneal inflammation model, cell migration assay and flowcytometry analysis, were used to investigate the role of chymase in recruiting mast cells. KEY
RESULTS: Chymase increased, by up to 5.4-fold, mast cell numbers in mouse peritoneum. Inhibitors of chymase, heat-inactivation of the enzyme, sodium cromoglycate and terfenadine, and pretreatment of mice with anti-intercellular adhesion molecule 1, anti-L-selectin, anti-CD11a and anti-CD18 antibodies dramatically diminished the chymase-induced increase in mast cell accumulation. These findings indicate that this effect of chymase is dependent on its enzymatic activity and activation of adhesion molecules. In addition, chymase provoked a significant increase in 5-HT and eotaxin release (up to 1.8- and 2.2-fold, respectively) in mouse peritoneum. Since 5-HT, eotaxin and RANTES can induce marked mast cell accumulation, these indirect mechanisms may also contribute to chymase-induced mast cell accumulation. Moreover, chymase increased the trans-endothelium migration of mast cells in vitro indicating it also acts as a chemoattractant. CONCLUSION AND IMPLICATIONS: The finding that mast cells accumulate in response to chymase implies further that chymase is a major pro-inflammatory mediator of mast cells. This effect of chymase, a major product of mast cell granules, suggests a novel self-amplification mechanism for mast cell accumulation in allergic inflammation. Mast cell stabilizers and inhibitors of chymase may have potential as a treatment of allergic disorders.
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29197072      PMCID: PMC5786453          DOI: 10.1111/bph.14117

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

1.  Animal research: reporting in vivo experiments: the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Expression and release of IL-29 by mast cells and modulation of mast cell behavior by IL-29.

Authors:  Shaoheng He; H Zhang; H Chen; H Yang; T Huang; Y Chen; J Lin; F Wang; X Chen; T-L Li; Pingchang Yang
Journal:  Allergy       Date:  2010-03-20       Impact factor: 13.146

3.  Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells.

Authors:  L B Schwartz; A M Irani; K Roller; M C Castells; N M Schechter
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

Review 4.  Mast cells: function and contents.

Authors:  L B Schwartz
Journal:  Curr Opin Immunol       Date:  1994-02       Impact factor: 7.486

5.  Mast cell degranulation mediates bronchoconstriction via serotonin and not via renin release.

Authors:  Manne Krop; Zeynep G Ozünal; Wenxia Chai; René de Vries; Durk Fekkes; Angelique M Bouhuizen; Ingrid M Garrelds; A H Jan Danser
Journal:  Eur J Pharmacol       Date:  2010-05-10       Impact factor: 4.432

6.  Mast cell chymase induces expression of chemokines for neutrophils in eosinophilic EoL-1 cells and mouse peritonitis eosinophils.

Authors:  Maki Terakawa; Yoshiaki Tomimori; Megumi Goto; Yoshiaki Fukuda
Journal:  Eur J Pharmacol       Date:  2006-05-09       Impact factor: 4.432

7.  Inhibitors of chymase as mast cell-stabilizing agents: contribution of chymase in the activation of human mast cells.

Authors:  S He; M D Gaça; A R McEuen; A F Walls
Journal:  J Pharmacol Exp Ther       Date:  1999-11       Impact factor: 4.030

8.  Mast cell recruitment after subcutaneous injection of RANTES in the sole of the rat paw.

Authors:  P Conti; M Reale; R C Barbacane; M Felaco; A Grilli; T C Theoharides
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

9.  Absence of platelet endothelial cell adhesion molecule-1 (CD31) leads to increased severity of local and systemic IgE-mediated anaphylaxis and modulation of mast cell activation.

Authors:  Mae-Xhum Wong; Donna Roberts; Paul A Bartley; Denise E Jackson
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

Review 10.  Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules.

Authors:  Giorgio Ciprandi; Maria Angela Tosca; Cristina Cosentino; Anna Maria Riccio; Giovanni Passalacqua; Giorgio Walter Canonica
Journal:  J Allergy Clin Immunol       Date:  2003-10       Impact factor: 10.793

View more
  3 in total

1.  FNF-12, a novel benzylidene-chromanone derivative, attenuates inflammatory response in in vitro and in vivo asthma models mediated by M2-related Th2 cytokines via MAPK and NF-kB signaling.

Authors:  Mohammad Abohassan; Mesfer Al Shahrani; Mohammad Y Alshahrani; Naseem Begum; Suresh Radhakrishnan; Prasanna Rajagopalan
Journal:  Pharmacol Rep       Date:  2021-09-01       Impact factor: 3.024

2.  Protease profile of normal and neoplastic mast cells in the human bone marrow with special emphasis on systemic mastocytosis.

Authors:  Dmitri Atiakshin; Igor Buchwalow; Peter Horny; Markus Tiemann
Journal:  Histochem Cell Biol       Date:  2021-01-25       Impact factor: 4.304

3.  Insights into Early-Pregnancy Mechanisms: Mast Cells and Chymase CMA1 Shape the Phenotype and Modulate the Functionality of Human Trophoblast Cells, Vascular Smooth-Muscle Cells and Endothelial Cells.

Authors:  Ningjuan Zhang; Anne Schumacher; Beate Fink; Mario Bauer; Ana Claudia Zenclussen; Nicole Meyer
Journal:  Cells       Date:  2022-03-29       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.